Page last updated: 2024-09-03

gsk peptide and perifosine

gsk peptide has been researched along with perifosine in 1 studies

Compound Research Comparison

Studies
(gsk peptide)
Trials
(gsk peptide)
Recent Studies (post-2010)
(gsk peptide)
Studies
(perifosine)
Trials
(perifosine)
Recent Studies (post-2010) (perifosine)
71124531140

Protein Interaction Comparison

ProteinTaxonomygsk peptide (IC50)perifosine (IC50)
Polyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)1.2
Ubiquitin carboxyl-terminal hydrolase isozyme L3Homo sapiens (human)0.05
RAC-alpha serine/threonine-protein kinaseHomo sapiens (human)5.3
Mitogen-activated protein kinase 14Homo sapiens (human)1.2

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Anderson, KC; Azab, AK; Azab, F; Chuma, S; Ghobrial, IM; Harris, B; Hong, F; Jia, X; Leduc, R; Leleu, X; Richardson, PG; Roccaro, A; Rodig, S; Rourke, M; Rubin, N; Sacco, A; Sportelli, P; Varticovski, L; Warren, D; Weller, E1

Trials

1 trial(s) available for gsk peptide and perifosine

ArticleYear
Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Feb-01, Volume: 16, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Male; Middle Aged; Oligopeptides; Phosphorylcholine; Prognosis; Proto-Oncogene Proteins c-akt; Recurrence; Waldenstrom Macroglobulinemia

2010